332 related articles for article (PubMed ID: 22743095)
1. [Protein tyrosine kinase inhibitors in cancer therapy].
Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
[TBL] [Abstract][Full Text] [Related]
2. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
3. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
4. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents.
Uecker A; Sicker M; Beckers T; Mahboobi S; Hägerstrand D; Ostman A; Böhmer FD
Anticancer Drugs; 2010 Sep; 21(8):759-65. PubMed ID: 20613486
[TBL] [Abstract][Full Text] [Related]
5. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
6. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
7. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinases as targets for cancer therapy.
Krause DS; Van Etten RA
N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
[No Abstract] [Full Text] [Related]
10. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
15. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
16. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in pediatric malignancies.
Skolnik JM; Adamson PC
Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies with imatinib in 2004].
Eckhardt S
Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
20. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]